Patents by Inventor Ranjit C. Desai

Ranjit C. Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190359574
    Abstract: The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 28, 2019
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. Desai, Rajiv Sharma, Vrajesh Pandya, Kalpesh Shah, Sunil Patel, Rakesh Chauhan, Ranjeet Nair, Vivek Joshi, Manoj Patel, Mrigendra Shukla
  • Patent number: 10246470
    Abstract: The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo[3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: April 2, 2019
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. Desai, Brijeshkumar Srivastava
  • Publication number: 20180346486
    Abstract: The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo [3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.
    Type: Application
    Filed: June 7, 2018
    Publication date: December 6, 2018
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. DESAI, Brijeshkumar SRIVASTAVA
  • Patent number: 10011609
    Abstract: The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: July 3, 2018
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. Desai, Brijeshkumar Srivastava
  • Patent number: 9840509
    Abstract: The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 12, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Ranjit C. Desai, Rajesh Bahekar, Dipam Patel, Kiran Shah
  • Publication number: 20170105937
    Abstract: The present invention relates to co-precipitates of olaparib and an ionic polymer and pharmaceutical composition containing the co-precipitates. Further, the present invention relates to a method of treating disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said composition.
    Type: Application
    Filed: October 17, 2016
    Publication date: April 20, 2017
    Inventors: Shafiq un Nabi SHEIKH, Mukesh UKAWALA, Tishir GANDHI, Brijesh Kumar SRIVASTAVA, Muthaiyyan Essakimuthu KANNAN, Ranjit C. DESAI
  • Patent number: 9598418
    Abstract: The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: March 21, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Brijesh K. Srivastava, Ranjit C. Desai, Pankaj R. Patel
  • Publication number: 20170007610
    Abstract: The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (?) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: January 23, 2015
    Publication date: January 12, 2017
    Inventors: Ranjit C. DESAI, Rajesh BAHEKAR, Vijay PRAJAPATI, Pankaj R. PATEL
  • Publication number: 20160376277
    Abstract: The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.
    Type: Application
    Filed: February 2, 2015
    Publication date: December 29, 2016
    Inventors: Ranjit C. DESAI, Rajesh BAHEKAR, Dipam PATEL, Kiran SHAH
  • Publication number: 20160257701
    Abstract: The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 8, 2016
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. DESAI, Brijeshkumar SRIVASTAVA
  • Patent number: 9394300
    Abstract: The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: July 19, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Ranjit C. Desai, Vrajesh Pandya, Pankaj Ramanbhai Patel
  • Publication number: 20160083380
    Abstract: Compounds of the general formula (I), including their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds and the intermediates involved in their preparation.
    Type: Application
    Filed: December 15, 2014
    Publication date: March 24, 2016
    Inventors: Ranjit C. DESAI, Harikishore PINGALI
  • Publication number: 20150299193
    Abstract: The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Application
    Filed: December 23, 2013
    Publication date: October 22, 2015
    Applicant: Cadila Healthcare Limited
    Inventors: Ranjit C. Desai, Vrajesh Pandya, Pankaj Ramanbhai Patel
  • Publication number: 20150291603
    Abstract: The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 15, 2015
    Inventors: Brijesh K. Srivastava, Ranjit C. Desai, Pankaj R. Patel
  • Publication number: 20150246025
    Abstract: The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 3, 2015
    Inventors: Ranjit C. Desai, Rajesh Bahekar, Pradip Jadav, Amitgiri Goswami, Pankaj Patel
  • Patent number: 7297715
    Abstract: A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 20, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ranjit C. Desai, Soumya Sahoo
  • Patent number: 6713508
    Abstract: A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: March 30, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Soumya P. Sahoo, Hiroo Koyama, Daniel J. Miller, Julia K. Boueres, Ranjit C. Desai
  • Patent number: 6645997
    Abstract: A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: November 11, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Soumya P. Sahoo, Hiroo Koyama, Daniel J. Miller, Julia K. Boueres, Ranjit C. Desai
  • Patent number: 6465497
    Abstract: Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ranjit C. Desai, Soumya P. Sahoo, Jeffrey P. Bergman, Victoria K. Lombardo, Edward J. Metzger, Hiroo Koyama
  • Publication number: 20020103242
    Abstract: A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Application
    Filed: October 29, 2001
    Publication date: August 1, 2002
    Inventors: Soumya P. Sahoo, Hiroo Koyama, Daniel J. Miller, Julia K. Boueres, Ranjit C. Desai